methotrexate

(redirected from Otrexup)
Also found in: Dictionary, Thesaurus, Medical.
Related to Otrexup: methotrexate

methotrexate

methotrexate, drug used in halting the growth of actively proliferating tissues. Introduced in the 1950s, it is used in the treatment of leukemia, psoriasis, and non-Hodgkin's lymphoma. By binding to an enzyme that controls the metabolism of folic acid, methotrexate interferes with synthesis of nucleic acids and therefore with tissue cell reproduction. Because of its immunosuppressive qualities, it is also used in the treatment of rheumatoid arthritis.
The Columbia Electronic Encyclopedia™ Copyright © 2022, Columbia University Press. Licensed from Columbia University Press. All rights reserved.

methotrexate

[‚meth·ə′trek‚sāt]
(pharmacology)
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
OTREXUP was the first US FDA-approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector for adults with severe active rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents, added the company.
Antares president and CEO, Dr Paul K Wotton, stated that Otrexup offers an attractive new option that is likely to benefit patients who have had an inadequate response to, or are intolerant of, oral methotrexate.
Antares Pharma, a company that develops, manufactures and markets needle-free injection systems for the self-administration of parenteral drugs, has received approval for OTREXUP, a single-dose, disposable auto-injector for the subcutaneous once-weekly administration of methotrexate from the US Food and Drug Administration (US FDA), it was reported yesterday.
The company stated that the claims in the OTREXUP patent are directed toward an injection system for methotrexate as well as a method for treating rheumatoid arthritis and other autoimmune diseases using an auto-injector or similar device for subcutaneous delivery of methotrexate.
M2 PHARMA-February 28, 2013-Antares Pharma Inc's OTREXUP NDA accepted by US FDA for review(C)2013 M2 COMMUNICATIONS
M2 EQUITYBITES-February 28, 2013-Antares Pharma Inc's OTREXUP NDA accepted by US FDA for review(C)2013 M2 COMMUNICATIONS http://www.m2.com
M2 EQUITYBITES-December 18, 2012-Antares Pharma Inc submits OTREXUP's NDA to FDA for treating rheumatoid arthritis(C)2012 M2 COMMUNICATIONS http://www.m2.com